Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | PDE5A | O76074 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.93 |
| ▸ | TSHR | P16473 | 7/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.93 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.93 |
| ▸ | MEN1 | O00255 | 11/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | USP2 | O75604 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | GBA1 | P04062 | 2/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277274 | 0.96 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7286130 | 0.92 | PDE5A (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14262933 | 0.92 | CYP1A2 (0.84) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1083763 | 0.87 | PDE5A (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7277479 | 0.85 | PDE5A (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1062736 | 0.85 | PDE5A (0.89) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1083926 | 0.84 | MAPT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL29754288 | 0.84 | MAPT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7279992 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7279378 | 0.84 | MEN1 (0.84) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| CN-1152867-C | Quinazoline derivatives as medicaments | �����ɷ� | 2004-06-09 | — | — | CN | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| CN-1333757-A | Quinazoline derivatives as medicaments | SCIOS INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | CYP1A2 1171/4885CYP3A4 267/4885CYP2D6 523/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | CYP1A2 834/4885CYP3A4 278/4885CYP2D6 247/4885 |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | CYP1A2 722/4885CYP3A4 1830/4885CYP2D6 2107/4885 |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | CYP1A2 722/4885CYP3A4 1830/4885CYP2D6 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.